The authors thank CEPI for insights into current planning considerations for Lassa fever vaccine trials and an overview of the preliminary results from the ENABLE study. We thank Melissa Wynn, Carrie Mills, Kevin Sprurgers, and Lovelyn Charles at Emergent BioSolutions for help with coordinating research efforts.